Clinical Trial, UK

New assay predicts TGN1412 side effects

23.01.2007

British immunologists claim they have developed a lab test, which for the first time replicates the unexpected side-effects seen in six patients, that received the experimental ‘superantibody‘ drug TGN1412 of the now defunct German TeGenero AG. At the time of the announcement, the British drug authority MHRA published its final report on the disastrous clinical trial that led to a systemic inflammation in all volunteers. Dr. Stephen Inglis, a member of the MHRA panel, announced “a publication on the new assay is in preparation”.

In contrast to all existing in vitro tests, which measure the immune effects of free TGN1412, the novel assay works with the immobilised antibody. “Effectively, we immobilise the antibody in a particular way, and that is the trick that stimulates the immune response”, says Inglis, who is director of the London-based National Institute for Biological Standards and Control (NIBSC). “The effect causes particular CD4 cells to release large amounts of cytokines and to begin to divide dramatically.” Every time, Inglis’ team immobilised TGN1412 either by dry coating to the wells of 96 well plates, or by capturing its Fc part by an anti-human Fc antibody to a surface or endothel cells, the researchers measured a strong proliferative response as well as a stimulated cytokine release by the immune cells. Concentrations ranging from 1-10 µg dry-coated TGN1412 per well boosted the production of interleukin 8 (IL-8), tumour necrosis factor (TNF) and IL-6 in vitro. On top of this, dry-coating of only 2µg TGN1412 per well led to a strong polyclonal proliferative response. With higher concentrations (100 or 1,000 µg/µl), equivalent to doses tested in cynomolgous macaques, either a low or no proliferation of immune cells was observed. Immobilisation of TGN1412 “appears to be a more effective way of presenting the drug to the cells”, concludes the MHRA, “possibly due to cross-linking” of the antibodies’ Fc part, as proposed ealier last year (see Euro­BiotechNews 5-6/2006). Inglis said, he believes that the test, once it has been validated, might be useful for screening immunmodulatory drug candidates.
“Binding antibodies to plastic surfaces seems to me a very artificial approach,” disagrees TeGenero’s founder Prof. Dr. Thomas Hünig. “But, if the results with the endothel cells are confirmed, they might point to an unexpected co-activating effect of these cells in vivo.” However, one cannot rely on an immuno assay alone, according to the researcher. Instead, future trials with immunomodulators similar to TGN1412 would require microdosing to avoid unexpected side effects, said Hünig. The expert doubts that the concept of Treg activation will be given a second chance by the regulatory authorities.

Ongoing compensation claims

Martyn Day, the solicitor of 4 of the 6 victims of the TGN1412 trial told EuroBiotechNews that he will continue to receive compensation, either from Tegenero’s CRO Parexel or from the legal successor of the bankrupt TeGenero AG. The firm’s liquidator, Frank Hanselmann, claimed that the company assets were sold as a whole “to a firm outside Germany”, but due to a non-disclosure agreement neither he nor the paid creditors or Tegenero’s ex-management can give any details on the purchase price or the company’s identity. However, Day told EuroBiotechNews that he will try to get access to the insolvency proceedings (reference number 1 IN 389/06 at Amtsgericht Würzburg) to find out, which company bought TeGenero. It remains open if the identity of TeGenero’s buyer will ever become public.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/article/new-assay-predicts-tgn1412-side-effects.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper